Nilofer Saba Azad

18PUBLICATIONS
261CO-AUTHORS
ChemotherapyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Oct 24, 2026
COMPANION-002: A Randomized Phase 2/3 Trial of Tovecimig Plus Paclitaxel versus Paclitaxel Alone as a Second-line Therapy in Patients with Advanced Biliary Tract Cancer.

|Aug 14, 2026
Clinical, Genomic, and Spatial Transcriptomic Features of Pancreatic Adenosquamous Carcinoma Support Subtype-Specific Therapeutic Strategies.

|Jul 16, 2026
First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts.

|Jun 30, 2026
A Randomized Phase II Study of Combination Atezolizumab and Varlilumab (CDX-1127) with or without Cobimetinib in Previously Treated Unresectable Biliary Tract Cancer.

|Sep 30, 2025
Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations.

James J Harding, Do-Youn Oh, Teresa Macarulla Mercade

|May 19, 2025
Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer.

Eric S Christenson, Won Jin Ho, Daniel Shu

Pageof 3

Frequent Collaborators

7 joint publications

Daniel Laheru

6 joint publications

Hao Wang

6 joint publications

Mark Yarchoan

5 joint publications

Elizabeth M Jaffee